Edition:
United States

Aveo Pharmaceuticals Inc (AVEO.OQ)

AVEO.OQ on NASDAQ Stock Exchange Capital Market

2.29USD
3:42pm EDT
Change (% chg)

$0.08 (+3.62%)
Prev Close
$2.21
Open
$2.22
Day's High
$2.35
Day's Low
$2.21
Volume
325,778
Avg. Vol
280,210
52-wk High
$4.24
52-wk Low
$0.63

Select another date:

Tue, May 8 2018

BRIEF-Aveo Reports Q1 Loss Per Share $0.08

* AVEO REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

SEC seeks to block ex-Aveo CFO's testimony about consulting counsel

The Securities and Exchange Commission is seeking to block the former chief financial officer of Aveo Pharmaceuticals Inc from testifying at his upcoming trial that he relied on lawyers before making statements the regulator claims were misleading.

BRIEF-Aveo Quarterly Loss Per Share $0.08

* AVEO REPORTS FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Aveo Pharmaceuticals ‍Entered Into Sales Agreement With Leerink Partners

* AVEO PHARMACEUTICALS SAYS ‍ENTERED INTO A SALES AGREEMENT WITH LEERINK PARTNERS - SEC FILING

BRIEF-AVEO Says EUSA Pharma Granted Positive NICE Recommendation For Fotivda

* AVEO ANNOUNCES EUSA PHARMA GRANTED POSITIVE NICE RECOMMENDATION FOR FOTIVDA® (TIVOZANIB) AS FIRST LINE TREATMENT FOR ADVANCED RENAL CELL CARCINOMA

Ex-Aveo Pharmaceuticals exec avoids max penalty in SEC fraud case

A federal magistrate judge on Friday ordered the former chief medical officer of Aveo Pharmaceuticals Inc to pay a $50,000 penalty, a third of what the U.S. Securities and Exchange Commission requested, to resolve civil fraud charges.

SEC seeks penalty, 5-year ban for ex-Aveo Pharmaceuticals exec

The U.S. Securities and Exchange Commission is pushing to have the former chief medical officer of Aveo Pharmaceuticals Inc pay a $150,000 penalty and be barred for five years from serving as an officer or director of a public company for committing fraud.

Aveo settles investor lawsuit over cancer drug for $15 mln, warrants

Aveo Pharmaceuticals Inc will settle claims it misled shareholders about the Food and Drug Administration's concerns regarding a kidney cancer drug it was developing by paying $15 million out of insurance and issuing warrants for affected investors to buy 2 million shares.

BRIEF-Aveo Pharma Entered Into Binding MoU With Class Representatives Regarding Settlement Of A 2013 Class Action Lawsuit

* AVEO PHARMACEUTICALS - ENTERED INTO BINDING MOU WITH CLASS REPRESENTATIVES BOB LEVINE & WILLIAM WINDHAM REGARDING SETTLEMENT OF A 2013 CLASS ACTION LAWSUIT

Select another date: